InVivo Therapeutics Holdings Corp. (04I.F)
- Previous Close
0.2545 - Open
0.2545 - Bid --
- Ask --
- Day's Range
0.2545 - 0.2545 - 52 Week Range
0.1360 - 1.4560 - Volume
28,178 - Avg. Volume
2,932 - Market Cap (intraday)
846,739 - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
www.invivotherapeutics.com6
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Compare To: 04I.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 04I.F
Valuation Measures
Market Cap
846.74k
Enterprise Value
-7.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.10
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.75
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.71%
Return on Equity (ttm)
-98.11%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.33M
Diluted EPS (ttm)
-3.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
8.58M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.03M
Company Insights: 04I.F
04I.F does not have Company Insights